EA Electronic Arts Inc.

Electronic Arts Announces Proposed Offering of Senior Notes

Electronic Arts Inc. (NASDAQ: EA) today announced that it intends to offer, subject to market and other conditions, senior notes in a public offering.

EA intends to use the net proceeds from the offering for general corporate purposes, including but not limited to acquisitions.

J.P. Morgan Securities LLC and BofA Securities, Inc. will act as joint book-running managers for the offering.

The offering of senior notes is being made pursuant to an effective shelf registration statement on Form S-3 that has previously been filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement, together with the accompanying prospectus, related to the offering has been filed with the SEC and is available on the SEC’s website, . Copies of the preliminary prospectus supplement and the accompanying prospectus related to the offering may be obtained by contacting: J.P. Morgan Securities LLC at (212) 834-4533 or BofA Securities, Inc. toll free at (800) 294-1322.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Electronic Arts

Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company develops and delivers games, content and online services for Internet-connected consoles, mobile devices and personal computers.

In fiscal year 2020, EA posted GAAP net revenue of $5.5 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality brands such as EA SPORTS™ FIFA, Battlefield™, Apex Legends™, The Sims™, Madden NFL, Need for Speed™, Titanfall™ and Plants vs. Zombies™. More information about EA is available at .

Safe Harbor for Forward-Looking Statements

Some statements set forth in this press release regarding Electronic Arts’ offering of senior notes contain forward-looking statements that are subject to change. Statements including words such as “anticipate,” “believe,” “expect,” “intend,” “estimate,” “plan,” “predict,” “seek,” “goal,” “will,” “may,” “likely,” “should,” “could” (and the negative of any of these terms), “future” and similar expressions also identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual events or actual future results to differ materially from those set forth in the forward-looking statements, including the following: Electronic Arts’ ability to effectively execute its business and capital plans, changes in general economic and market conditions, including the stock market, changes in interest rates, including interest rate resets and other factors described in Electronic Arts’ SEC filings (including the preliminary prospectus supplement and accompanying prospectus filed in relation to the offering of senior notes, Electronic Arts’ latest Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2020 and Electronic Arts’ Annual Report on Form 10-K for the fiscal year ended March 31, 2020). If any of these risks or uncertainties materializes, the potential benefits of the offering of senior notes may not be realized, Electronic Arts’ operating results and financial performance could suffer, and actual results could differ materially from the expectations described in these forward-looking statements. There is no assurance that the offering of the senior notes will be completed or completed as described above. These forward-looking statements speak only as of the date of this press release. Electronic Arts assumes no obligation to update these forward-looking statements.

EN
09/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Electronic Arts Inc.

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
ACRS ACLARIS THERAPEUTICS INC.
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ORIC KEROS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PLTK SANA BIOTECHNOLOGY
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
EWTX PEPGEN INC
SLDB EDGEWISE THERAPEUTICS INC
DDI SOLID BIOSCIENCES INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B APOGEE THERAPEUTICS INC
DNTH EMBRACER GROUP AB
ORKA DIANTHUS THERAPEUTICS INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
IMA JADE BIOSCIENCES INC
IMAGENEBIO INC.
Michael Piccolo
  • Michael Piccolo

Daily Recap: TRIP, PUIG/EL, JEF/8316, JHG/VCTR, EA, ZION, BLX, PERF, A...

INDUSTRY NEWS - Convertible Bonds: Record Average Deal Sizes as Nebius, Oracle Drive $30.3 Billion in YTD 2026 Issuance. According to Bloomberg, the U.S. convertible bond market is on pace for another blockbuster year, with year-to-date issuance reaching $30.3 billion through late March 2026; a 76%

Michael Piccolo
  • Michael Piccolo

Daily Recap: SSTK/GETY, BCRX, DSGR, AVAV, JHG/VCTR, MA, GIS, LNSR/ALC,...

BioCryst Pharmaceuticals, Inc. (BCRX - $9.30)Laura Chico's Thoughts On Betaville Rumors; Takeout Not Central To Our Thesis, But Possible; Remains OUTPERFORM. On Monday, Betaville published a potential comment indicating BCRX could be an M&A target for a US-listed biopharma over $15 billion. We

ResearchPool Subscriptions

Get the most out of your insights

Get in touch